$2.49
5.96% yesterday
Nasdaq, Aug 22, 10:00 pm CET
ISIN
US02262M3088
Symbol
ALZN

Alzamend Neuro Inc Stock price

$2.49
-0.71 22.19% 1M
-5.54 68.99% 6M
-7.95 76.15% YTD
-28.02 91.84% 1Y
-1,307.01 99.81% 3Y
-18,222.51 99.99% 5Y
-18,222.51 99.99% 10Y
-18,222.51 99.99% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.14 5.96%
ISIN
US02262M3088
Symbol
ALZN
Industry

Key metrics

Basic
Market capitalization
$7.2m
Enterprise Value
$3.3m
Net debt
positive
Cash
$4.0m
Shares outstanding
780.0k
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.8
Financial Health
Equity Ratio
86.2%
Return on Equity
-128.7%
ROCE
-113.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-4.5m | $-11.8m
EBIT
$-4.5m | $-11.3m
Net Income
$-5.2m | $-8.7m
Free Cash Flow
$-6.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
55.0% | -165.9%
EBIT
54.8% | -151.9%
Net Income
48.1% | -71.0%
Free Cash Flow
18.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-7.3
FCF per Share
$-8.8
Short interest
7.3%
Employees
6
Rev per Employee
$0.0
Show more

Is Alzamend Neuro Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Alzamend Neuro Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Alzamend Neuro Inc forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Alzamend Neuro Inc forecast:

Buy
75%
Hold
25%

Financial data from Alzamend Neuro Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Apr '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.08 3.08
11% 11%
-
- Research and Development Expense 1.41 1.41
78% 78%
-
-4.45 -4.45
55% 55%
-
- Depreciation and Amortization 0.05 0.05
0% 0%
-
EBIT (Operating Income) EBIT -4.50 -4.50
55% 55%
-
Net Profit -5.16 -5.16
48% 48%
-

In millions USD.

Don't miss a Thing! We will send you all news about Alzamend Neuro Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alzamend Neuro Inc Stock News

Neutral
GlobeNewsWire
26 days ago
Session Topic is the I nnovation and Current Directions in Military Suicide Prevention, Research, and Programs Presentation Title is Quantitate Differences in Lithium Brain-to-Plasma Exposure in PTSD Subjects Between AL001 and Lithium Carbonate ATLANTA, July 28, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company, focused on deve...
Neutral
GlobeNewsWire
about one month ago
During the year ended April 30, 2025, net cash provided by financing activities was $10.4 million Stockholder equity of $4.0 million at April 30, 2025, including $3.9 million of cash In May 2025, Alzamend dosed the first patient for the healthy human patients for the AL001 “Lithium in Brain” Studies at Massachusetts General Hospital In June 2025, Alzamend completed the final closing of its $5 m...
Neutral
GlobeNewsWire
2 months ago
ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease (“Alzheimer's”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that it has completed the final closing of its...
More Alzamend Neuro Inc News

Company Profile

Alzamend Neuro, Inc. is a preclinical stage biopharmaceutical company, which engages in the manufacture of pharmaceutical products. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Tampa, FL.

Head office United States
CEO Stephan Jackman
Employees 6
Founded 2016
Website alzamend.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today